Loading...
Market
Story
Merck's CAPVAXIVE™ ($MRK) Vaccine Shows Positive Results in At-Risk Adults
Oct 16, 2024, 10:51 AM
Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) has demonstrated positive immune responses in adults with an increased risk for pneumococcal disease. The new Phase 3 data was shared at IDWeek 2024, highlighting the vaccine's efficacy in providing immune protection against pneumococcal disease, a significant concern for at-risk populations. The vaccine's development is a notable achievement for Merck ($MRK).
View original story
Similar markets
Yes • 50%
No • 50%
Approved in all major markets • 25%
Approved in some major markets • 25%
Not approved in any major markets • 25%
Approval status pending • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
